
|Videos|November 5, 2013
Combination Therapies in Melanoma
Author(s)Omid Hamid, MD
Omid Hamid, MD, discusses promising combination therapies for the treatment of melanoma.
Advertisement
Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses promising combination therapies for the treatment of melanoma.
Clinical Pearls
- In the metastatic setting, BRAF, MEK, and checkpoint inhibition is forthcoming
- There are currently trials looking at anti-PD-1 with anti-CTLA-4 therapy
- Dr. Hamid is hopeful that in the future, other targeted immunotherapies and FDA-approved targeted treatment combinations will show survival benefit and be approved and available for use.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































